- Trials with a EudraCT protocol (322)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
322 result(s) found for: Minimal Change Disease.
Displaying page 1 of 17.
EudraCT Number: 2017-001206-16 | Sponsor Protocol Number: 121934 | Start Date*: 2017-09-15 | ||||||||||||||||
Sponsor Name:Aarhus University hospital | ||||||||||||||||||
Full Title: Treatment of primary minimal change nephropathy. A randomized, open-labeled, non-inferiotiry study on prednisolone and vitamin D | ||||||||||||||||||
Medical condition: Minimal Change Nephropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011170-15 | Sponsor Protocol Number: P071226 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Evaluation de l'efficacité d'une corticothérapie à faible dose, associée à l'acide mycophénolique (Myfortic) dans le traitement d'attaque du syndrome néphrotique à lésions glomérulaires minimes de ... | |||||||||||||
Medical condition: Syndrome néphrotique à lésions glomérulaires minimes (SNLGM). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006750-17 | Sponsor Protocol Number: NEMO | Start Date*: 2009-04-14 | |||||||||||||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||||||||||||
Full Title: A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with st... | |||||||||||||||||||||||
Medical condition: Nephrotic Syndrome secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000621-27 | Sponsor Protocol Number: RTRX-RE021-201 | Start Date*: 2022-10-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Travere Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (E... | |||||||||||||||||||||||||||||||||
Medical condition: Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Al... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Temporarily Halted) SE (Restarted) PL (Ongoing) DE (Restarted) IT (Ongoing) NL (Restarted) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002430-76 | Sponsor Protocol Number: 15OKG16 | Start Date*: 2016-11-17 | ||||||||||||||||||||||||||
Sponsor Name:Radboudumc, Amalia Children’s Hospital, Department of Pediatrics | ||||||||||||||||||||||||||||
Full Title: Double-blind, randomized, placebo controlled noninferiority intervention study to REduce STEroids in Relapsing Nephrotic syndrome | ||||||||||||||||||||||||||||
Medical condition: Nephrotic syndrome relapse in children | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) BE (Ongoing) DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014292-52 | Sponsor Protocol Number: GRIM1002 | Start Date*: 2009-10-28 | |||||||||||
Sponsor Name:Imperial College NHS trust | |||||||||||||
Full Title: Tacrolimus vs prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease: A Randomised Control Trial | |||||||||||||
Medical condition: Nephrotic syndrome with lesion minimal change glomerulonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002630-39 | Sponsor Protocol Number: 3tcAZ | Start Date*: 2011-10-25 |
Sponsor Name:Oslo University Hospital Rikshospitalet | ||
Full Title: MICROVASCULAR RESISTANCE IN WOMEN WITH CHEST PAIN AND NO OR MINIMAL CORONARY ARTERY DISEASE | ||
Medical condition: Investigation of otherwise healthy women with chest pain without significant stenoses in their epicardial coronary arteries. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002255-42 | Sponsor Protocol Number: MK-3222-010 | Start Date*: 2013-01-10 | |||||||||||
Sponsor Name:Sun Pharma Global FZE | |||||||||||||
Full Title: A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optiona... | |||||||||||||
Medical condition: Moderate-to-Severe Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005202-98 | Sponsor Protocol Number: 80202135IIM2001 | Start Date*: 2022-10-05 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myo... | |||||||||||||
Medical condition: Active Idiopathic Inflammatory Myopathies (IIM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) CZ (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013262-84 | Sponsor Protocol Number: V00400SB201 | Start Date*: 2009-10-28 | |||||||||||
Sponsor Name:PIERRE FABRE DERMATOLOGIE | |||||||||||||
Full Title: A randomised, controlled, multidose, multicentre, adaptive phase II/III study in infants with proliferating infantile hemangiomas requiring systemic therapy to compare four regimens of propranolol ... | |||||||||||||
Medical condition: Proliferating Infantile Hemangioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) HU (Completed) LT (Completed) CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003366-27 | Sponsor Protocol Number: R-SRNS17 | Start Date*: 2017-12-21 |
Sponsor Name:Radboud University Nijmegen Medical Center | ||
Full Title: Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone. | ||
Medical condition: Idiopathic nephrotic syndrome Focal segmental glomerulosclerosis Minimal change disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001370-20 | Sponsor Protocol Number: OPV116910 | Start Date*: 2014-11-26 | |||||||||||
Sponsor Name:Glaxo Group Ltd | |||||||||||||
Full Title: OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris | |||||||||||||
Medical condition: Pemphigus Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) HR (Completed) GR (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006164-59 | Sponsor Protocol Number: H80-BP-GWBG | Start Date*: 2006-05-18 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: An Open Label Study Comparing Exenatide with Basal Insulin in Achieving an HbA1c of <_7.4% with Minimum Weight Gain, in Type 2 Diabetes Patients who are not Achieving Adequate HbA1c Control on Oral... | ||
Medical condition: Type 2 Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005987-67 | Sponsor Protocol Number: AK802 | Start Date*: 2021-12-22 | |||||||||||
Sponsor Name:Akari Therapeutics Plc | |||||||||||||
Full Title: A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pem... | |||||||||||||
Medical condition: moderate to severe bullous pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005708-18 | Sponsor Protocol Number: 14081962 | Start Date*: 2010-06-04 |
Sponsor Name:Queen Mary University of London | ||
Full Title: Prevention of metabolic complications of glucocorticoid excess | ||
Medical condition: Rheumatoid arthritis, SLE, Polymyalgia rheumatica, Disthyroid eye disease, Cushing's syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000719-15 | Sponsor Protocol Number: CNTO1959PSO3001 | Start Date*: 2014-10-24 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve... | |||||||||||||
Medical condition: Moderate to Severe Plaque Type Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000720-18 | Sponsor Protocol Number: CNTO1959PSO3002 | Start Date*: 2015-02-11 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve... | |||||||||||||
Medical condition: Moderate to Severe Plaque Type Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005911-30 | Sponsor Protocol Number: ARGX-113-2106 | Start Date*: 2022-12-27 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 2, Randomized, Placebo-controlled, Parallel Group, Double-blind, Proof-of-concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sj... | |||||||||||||
Medical condition: Primary Sjögren’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001740-54 | Sponsor Protocol Number: MK-3222-012 | Start Date*: 2013-12-16 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc. | |||||||||||||
Full Title: A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by... | |||||||||||||
Medical condition: Moderate-to-Severe Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004585-25 | Sponsor Protocol Number: I1F-MC-RHCF | Start Date*: 2017-05-26 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) SE (Completed) DK (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.